- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03427541
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
February 7, 2018 updated by: Zhang Helong, Tang-Du Hospital
A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases
An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases
Study Overview
Detailed Description
A multi-centre real-world non-interventional observational study to explore prognoses and clinical treatments of the patients with non-small lung cancer complicated with oligometastases
Study Type
Observational
Enrollment (Anticipated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Recruiting
- China-Japan Friendship Hospital
-
Contact:
- Deruo Liu, PhD
- Phone Number: 0086-13801186957
- Email: deruoliu@vip.sina.com
-
Principal Investigator:
- Deruo Liu, PhD
-
Beijing, Beijing, China, 100853
- Recruiting
- China PLA General Hospital
-
Contact:
- Yang Liu, PhD
- Phone Number: 0086-13501009331
- Email: sunny301x@sina.com
-
Principal Investigator:
- Yang Liu, PhD
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Yin Li, PhD
- Phone Number: 0086-13903838752
- Email: liyin825@aliyun.com
-
Principal Investigator:
- Yin Li, PhD
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital Affiliated to Huazhong Technology Hospital
-
Contact:
- Xiangning Fu, PhD
- Phone Number: 0086-13607150390
- Email: Fuxn2006@aliyun.com
-
Principal Investigator:
- Xiangning Fu, PhD
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Jiangsu Cancer Hospital
-
Contact:
- Lin Xu, PhD
- Phone Number: 0086-13605168383
- Email: xulin83@vip.sina.com
-
Principal Investigator:
- Lin Xu, PhD
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Recruiting
- Xi'an Tangdu Hospital
-
Contact:
- Xiaofei Fu, PhD
- Phone Number: 0086-15009266699
- Email: lxfchest@fmmu.edu.cn
-
Principal Investigator:
- Xiaofei Li, PhD
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Principal Investigator:
- Heng Zhao, PhD
-
Contact:
- Heng Zhao, PhD
- Phone Number: 0086-13701865603
- Email: h_zhao28@163.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Huaxi Hospital Affiliated to Sichuan University
-
Contact:
- Lunxu Liu, PhD
- Phone Number: 0086-13608236600
- Email: lunxu_liu@aliyun.com
-
Principal Investigator:
- Lunxu Liu, PhD
-
-
Tianjin
-
Tianjin, Tianjin, China, 300051
- Recruiting
- Tianjin Chest Hospital
-
Contact:
- Xun Zhang, PhD
- Phone Number: 0086-18602212679
- Email: zhangxun69@163.com
-
Principal Investigator:
- Xun Zhang, PhD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- First Hospital Affiliated to Zhejiang University
-
Contact:
- Jian Hu, PhD
- Phone Number: 0086-13605708283
- Email: hujian_med@163.com
-
Principal Investigator:
- Jian Hu, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Pathologically diagnosed patients with non-small cell lung cancer
Description
Inclusion Criteria:
- Pathologically diagnosed patients with non-small cell lung cancer;
- Tumor metastases in one organ (no more than 3 metastases);
Exclusion Criteria:
- Patients with intrapulmonary metastases or multiple primary tumors;
- Patients with pleural dissemination or invasion of extrapulmonary organs;
- Patients with supraclavicular lymph node metastasis;
- Patients with systematic diseases that would influence patient survivals;
- Patients with no records for visits;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with surgeries
NSCLC patients with surgeries
|
Surgeries
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 2014 - 2017
|
Overall survival
|
2014 - 2017
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-free survival
Time Frame: 2014 - 2017
|
Disease-free survival
|
2014 - 2017
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 31, 2017
Primary Completion (Anticipated)
April 30, 2018
Study Completion (Anticipated)
April 30, 2018
Study Registration Dates
First Submitted
February 2, 2018
First Submitted That Met QC Criteria
February 7, 2018
First Posted (Actual)
February 9, 2018
Study Record Updates
Last Update Posted (Actual)
February 9, 2018
Last Update Submitted That Met QC Criteria
February 7, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WTONG05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Jiangxi Provincial People's HopitalNot yet recruitingNon-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer RecurrentChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Surgeries
-
The First Affiliated Hospital of Guangzhou Medical...CompletedNSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
The First Affiliated Hospital of Guangzhou Medical...UnknownNon-small Cell Lung CancerChina
-
Henan Cancer HospitalLinkDoc Technology (Beijing) Co. Ltd.Unknown
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.Completed
-
Jiangsu Cancer Institute & HospitalCompletedNon Small Cell Lung CancerChina
-
China-Japan Friendship HospitalLinkDoc Technology (Beijing) Co. Ltd.CompletedNon-small Cell Lung CancerChina
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingNeonatal Disorder